AIDS 2021 Oct 13. Epub 2021 Oct 13.
Men's Health Foundation, Los Angeles, California Broward Health Medical Center, Fort Lauderdale, Florida Augusta University Medical Center, Augusta, Georgia Triple O Research Institute PA, West Palm Beach, Florida Wellness Center UMC of Southern Nevada, Las Vegas, Nevada Central Texas Clinical Research, Austin, Texas Long Beach Education and Research Consultants, Long Beach, California Brii Biosciences, Durham ViiV Healthcare, Research Triangle Park, North Carolina GlaxoSmithKline, Upper Providence, Pennsylvania, USA GlaxoSmithKline, Mississauga, Ontario, Canada ViiV Healthcare, Tres Cantos, Spain Janssen Research & Development, Beerse, Belgium.
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral activity and safety of CAB+RPV long-acting administered every 2 months (Q2 M) in adults living with HIV-1 who previously received daily oral CAB+RPV in LATTE (NCT01641809).
Design: A phase 2b, multicenter, open-label, rollover study. Read More